Dong-A ST Co Overview
- Year Founded
-
1932
- Status
-
Public
- Employees
-
1,691
- Stock Symbol
-
170900
- Investments
-
14
- Share Price
-
$25.02
- (As of Friday Closing)
Dong-A ST Co General Information
Description
Dong-A ST Co Ltd is a Korea-based company principally engaged in the manufacturing and distribution of specialty pharmaceuticals. The company also involves in the provision of medical devices, diagnostic detection, as well as overseas sale business. Its in-house developed original drugs are used for gastritis treatment, erectile dysfunction treatment, functional dyspepsia, oxazolidinone class antibiotic, and diabetes treatment.
Contact Information
Website
www.donga-st.comCorporate Office
- 64 Cheonho-daero
- Dongdaemun-gu
- Seoul, 02587
- South Korea
Corporate Office
- 64 Cheonho-daero
- Dongdaemun-gu
- Seoul, 02587
- South Korea
Dong-A ST Co Stock Performance
As of 20-Nov-2026, Dong-A ST Co’s stock price is $25.02. Its current market cap is $241M with 9.6M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $25.02 | $25.52 | $20.42 - $38.92 | $241M | 9.6M | 8.49K | $0.53 |
Dong-A ST Co Financials Summary
As of 30-Jun-2026, Dong-A ST Co has a trailing 12-month revenue of $593M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 400,893 | 518,596 | 485,900 | 535,797 |
| Revenue | 593,236 | 568,308 | 511,470 | 507,844 |
| EBITDA | 29,696 | 5,400 | 14,194 | 27,447 |
| Net Income | 5,988 | (20,091) | (896) | 8,507 |
| Total Assets | 877,911 | 980,581 | 944,849 | 996,183 |
| Total Debt | 316,078 | 372,953 | 336,505 | 315,598 |
Dong-A ST Co Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Dong-A ST Co Comparisons
Industry
Financing
Details
Dong-A ST Co Competitors (39)
One of Dong-A ST Co’s 39 competitors is Astrogen, a Venture Capital-Backed company based in Daegu, South Korea.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Astrogen | Venture Capital-Backed | Daegu, South Korea | ||||
| Astellas Pharma | Corporation | Tokyo, Japan | ||||
| SK Biopharmaceuticals | Corporation | Seongnam, South Korea | ||||
| Savara | Formerly VC-backed | Yardley, PA | ||||
| CTI BioPharma | Formerly VC-backed | Seattle, WA |
Dong-A ST Co Patents
Dong-A ST Co Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026024144-A1 | Novel compound as polymerase theta inhibitor, and pharmaceutical composition comprising thereof | Pending | 26-Jul-2024 | ||
| WO-2025254414-A1 | Ahr modulator compound with improved solubility | Pending | 03-Jun-2024 | ||
| WO-2025254418-A1 | Crystalline polymorph of aminopyrimidine derivative and preparation method therefor | Pending | 03-Jun-2024 | ||
| AU-2024374922-A1 | Pharmaceutical composition for prevention or treatment of nonalcoholic fatty liver disease | Pending | 06-Nov-2023 | ||
| EP-4806437-A1 | Pharmaceutical composition for prevention or treatment of nonalcoholic fatty liver disease | Pending | 06-Nov-2023 | A61K31/506 |
Dong-A ST Co Signals
Dong-A ST Co Investments & Acquisitions (14)
Dong-A ST Co’s most recent deal was a Later Stage VC with People & Technology for . The deal was made on 07-Apr-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| People & Technology | 07-Apr-2026 | Later Stage VC | Electronic Equipment and Instruments | ||
| Ecowin | 28-May-2025 | Merger/Acquisition | Agricultural Chemicals | ||
| Idience | 20-May-2024 | Later Stage VC | Drug Discovery | ||
| BreezeBio | 23-Jan-2024 | Later Stage VC | Drug Delivery | ||
| AbTis | 20-Dec-2023 | Merger/Acquisition | Biotechnology |
Dong-A ST Co ESG
Risk Overview
Risk Rating
Updated June, 30, 2025
31.18 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,271
Rank
Percentile
Pharmaceuticals
Industry
of 908
Rank
Percentile
Pharmaceuticals
Subindustry
of 406
Rank
Percentile
Dong-A ST Co Exits (2)
Dong-A ST Co’s most recent exit was on 08-Nov-2022 from MetaVia (Biotechnology). The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| MetaVia (Biotechnology) | 08-Nov-2022 | Completed |
|
||
| ScienceMedic | 01-Mar-2015 | Seed Round | Completed |
Dong-A ST Co Affiliates
Subsidiaries (3)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| AbTis | Suwon, South Korea | 2016 | |
| Ecowin | Daegu, South Korea | 2008 | |
| Dong-A Chammed | Gunpo-si, South Korea | 2005 |
Dong-A ST Co FAQs
-
When was Dong-A ST Co founded?
Dong-A ST Co was founded in 1932.
-
Where is Dong-A ST Co headquartered?
Dong-A ST Co is headquartered in Seoul, South Korea.
-
What is the size of Dong-A ST Co?
Dong-A ST Co has 1,691 total employees.
-
What industry is Dong-A ST Co in?
Dong-A ST Co’s primary industry is Drug Discovery.
-
Is Dong-A ST Co a private or public company?
Dong-A ST Co is a Public company.
-
What is Dong-A ST Co’s stock symbol?
The ticker symbol for Dong-A ST Co is 170900.
-
What is the current stock price of Dong-A ST Co?
As of 20-Nov-2026 the stock price of Dong-A ST Co is $25.02.
-
What is the current market cap of Dong-A ST Co?
The current market capitalization of Dong-A ST Co is $241M.
-
What is Dong-A ST Co’s current revenue?
The trailing twelve month revenue for Dong-A ST Co is $593M.
-
Who are Dong-A ST Co’s competitors?
Astrogen, Astellas Pharma, SK Biopharmaceuticals, Savara, and CTI BioPharma are some of the 39 competitors of Dong-A ST Co.
-
What is Dong-A ST Co’s annual earnings per share (EPS)?
Dong-A ST Co’s EPS for 12 months was $0.53.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process